MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Immunocore Holdings PLC ADR

Închisă

36.02 0.14

Rezumat

Modificarea prețului

24h

Curent

Minim

35.27

Maxim

36.59

Indicatori cheie

By Trading Economics

Venit

29M

5M

Vânzări

9.8M

94M

Marjă de profit

5.35

Angajați

493

EBITDA

13M

-3.6M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+84.34% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

270M

1.8B

Deschiderea anterioară

35.88

Închiderea anterioară

36.02

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 iul. 2025, 21:01 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 20:46 UTC

Câștiguri

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 iul. 2025, 20:39 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 20:36 UTC

Câștiguri

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 iul. 2025, 20:16 UTC

Achiziții, Fuziuni, Preluări

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 iul. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 iul. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 iul. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 iul. 2025, 18:24 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 iul. 2025, 18:19 UTC

Câștiguri

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 iul. 2025, 18:11 UTC

Achiziții, Fuziuni, Preluări

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 iul. 2025, 18:11 UTC

Câștiguri

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 iul. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 iul. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 iul. 2025, 16:28 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Energy & Utilities Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 16:04 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 iul. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 iul. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 iul. 2025, 15:47 UTC

Market Talk
Câștiguri

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparație

Modificare preț

Immunocore Holdings PLC ADR Așteptări

Obiectiv de preț

By TipRanks

84.34% sus

Prognoză pe 12 luni

Medie 66.75 USD  84.34%

Maxim 100 USD

Minim 33 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruImmunocore Holdings PLC ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

7

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

27.895 / 30.16Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.